SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

cadisegliatin

VTVT·vTv Therapeutics Inc.
BULLISH
Drug Impact Rating7/10
Trial phase
Phase 3
Time to market
If Phase 3 CATT1 results are positive (mid 2027), an FDA submission (NDA) would likely follow in late 2027 or 2028, with potential approval in 2028-2029, assuming no regulatory setbacks.
Why 7/10
The next hard, dated catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027 (roughly 7 months from now). Cadisegliatin is vTv's lead and essentially only late-stage asset, making this a make-or-break binary event for a company with a ~$83M market cap. However, the readout is still ~7 months away, and vTv has a small pipeline beyond cadisegliatin (other early-stage programs), so it is not a pure single-asset binary at the 9-10 level. Score of 7 reflects a high-impact pivotal readout within ~6-12 months on the company's dominant asset.
Actionable Insight BULLISH

The next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.

Price Chart

Loading chart...

Executive Summary

Cadisegliatin (TTP399) is vTv Therapeutics' lead asset, an oral, liver-selective glucokinase activator being developed as a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D). The Phase 3 CATT1 trial completed enrollment with 166 patients in October 2026, with topline results expected mid 2027. The drug has FDA Breakthrough Therapy designation (May 2026) and Orphan Drug Designation (October 2026). Phase 2 SimpliciT-1 data showed HbA1c improvement and fewer severe hypoglycemia events. vTv is a single-asset, late-stage biotech with a market cap around $83 million and a mean analyst price target of $56 (166% upside from $21.03), but the stock trades near its 52-week low, reflecting execution risk and the long wait for the pivotal readout.

How It Works

Cadisegliatin is a pill that activates an enzyme called glucokinase specifically in the liver. This enzyme acts as a glucose sensor, helping the liver better regulate blood sugar levels. Because it works only in the liver (liver-selective), it is designed to lower blood sugar without causing dangerously low blood sugar (hypoglycemia), a major risk with insulin therapy. It is being studied as an add-on (adjunctive) therapy to insulin for people with type 1 diabetes, meaning they would still take insulin but could potentially need less of it and have fewer dangerous lows.

Trial Status

The pivotal Phase 3 CATT1 study completed enrollment in October 2026 with 166 participants randomized. Topline results are expected around mid 2027. A separate Phase 2a pilot study (Hybrid CATT1) evaluating cadisegliatin in patients using hybrid closed-loop insulin pumps began enrolling in October 2026. The Phase 2 SimpliciT-1 study (published in Diabetes Care, 2021) showed HbA1c improvement and fewer severe hypoglycemia events with a favorable safety profile.

The Two-Sided Case

▲ Bull Case5
Cadisegliatin has FDA Breakthrough Therapy designation (May 2026) and Orphan Drug Designation (October 2026), signaling regulatory interest and potential for accelerated development and priority review.
Phase 2 SimpliciT-1 data showed HbA1c improvement and fewer severe hypoglycemia events, a compelling profile for an oral adjunctive therapy in T1D where no oral adjunctive options currently exist.
Analyst consensus is strongly bullish: 12 analysts rate it Buy/Strong Buy with a mean price target of $56, implying 166% upside from the current ~$21 stock price near its 52-week low.
Institutional holders include Millennium Management, FMR LLC (Fidelity), and Baker Bros. Advisors, with several funds adding or doubling positions in Q2 2026.
The T1D adjunctive therapy market is underserved; an effective oral drug that reduces hypoglycemia risk could address a large unmet need.
▼ Bear Case5
Phase 3 CATT1 topline results are not expected until mid 2027, leaving a long period with no binary catalyst during which the stock could drift or face dilution.
The company reported a Q3 2026 net loss of $11.62 million, and with no approved products generating revenue, vTv will likely need to raise capital, causing shareholder dilution.
The drug was placed on clinical hold by the FDA in July 2024 (lifted March 2025), indicating regulatory risk and potential for future holds if safety signals emerge.
As a single-asset-focused company, any negative CATT1 readout would be devastating for the stock, which already trades near its 52-week low of $20.56.
Competition from advancing insulin pump technology (hybrid closed-loop systems) and other adjunctive therapies could limit cadisegliatin's commercial opportunity even if approved.

Upcoming Catalysts

  • Phase 3 CATT1 topline results expected mid 2027
  • Phase 2a Hybrid CATT1 pilot study interim data (timing not specified)
  • Potential partnership or licensing deal for cadisegliatin
  • FDA regulatory milestones given Breakthrough Therapy designation

Source Filing

The SecBot filing or press-release report that triggered this drug report:

vTv Therapeutics Inc. PRESS-RELEASE VTVT ·Originating report

Sources · 8

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 seekingalpha.com4 markets.businessinsider.com5 morningstar.com6 empr.com7 nasdaq.com8 nasdaq.com